Log in

Motus GI Stock Forecast, Price & News

-0.01 (-0.98 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $1.01
50-Day Range
MA: $1.06
52-Week Range
Now: $1.01
Volume39,875 shs
Average Volume121,517 shs
Market Capitalization$29.24 million
P/E RatioN/A
Dividend YieldN/A
Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.
Read More
Motus GI logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:MOTS



Sales & Book Value

Annual Sales$110,000.00
Book Value$0.64 per share


Net Income$-23,090,000.00
Net Margins-16,834.35%


Market Cap$29.24 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.01 (-0.98 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOTS News and Ratings via Email

Sign-up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Motus GI (NASDAQ:MOTS) Frequently Asked Questions

How has Motus GI's stock been impacted by Coronavirus (COVID-19)?

Motus GI's stock was trading at $1.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MOTS shares have decreased by 2.9% and is now trading at $1.01.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Motus GI?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Motus GI

When is Motus GI's next earnings date?

Motus GI is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Motus GI

How were Motus GI's earnings last quarter?

Motus GI Holdings Inc (NASDAQ:MOTS) posted its earnings results on Tuesday, August, 11th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.06. Motus GI had a negative return on equity of 139.08% and a negative net margin of 16,834.35%.
View Motus GI's earnings history

What price target have analysts set for MOTS?

5 analysts have issued 12 month price objectives for Motus GI's shares. Their forecasts range from $2.50 to $7.00. On average, they anticipate Motus GI's stock price to reach $3.62 in the next twelve months. This suggests a possible upside of 258.4% from the stock's current price.
View analysts' price targets for Motus GI

Are investors shorting Motus GI?

Motus GI saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 476,900 shares, a decline of 63.6% from the August 15th total of 1,310,000 shares. Based on an average trading volume of 89,000 shares, the short-interest ratio is presently 5.4 days. Approximately 1.8% of the shares of the company are short sold.
View Motus GI's Short Interest

Who are some of Motus GI's key competitors?

What other stocks do shareholders of Motus GI own?

Who are Motus GI's key executives?

Motus GI's management team includes the following people:
  • Mr. Timothy P. Moran, CEO & Director (Age 47)
  • Mr. Mark Pomeranz, Pres, COO & Director (Age 58)
  • Mr. Andrew Lawrence Taylor, Chief Financial Officer (Age 48)

When did Motus GI IPO?

(MOTS) raised $21 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Piper Jaffray served as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

What is Motus GI's stock symbol?

Motus GI trades on the NASDAQ under the ticker symbol "MOTS."

Who are Motus GI's major shareholders?

Motus GI's stock is owned by a variety of retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (0.48%) and Hudson Bay Capital Management LP (0.28%). Company insiders that own Motus GI stock include Andrew Lawrence Taylor, David P Hochman, Gary E Jacobs, Larry N Feinberg, Life Sciences Maste Perceptive, Mark Pomeranz and Timothy P Moran.
View institutional ownership trends for Motus GI

Which major investors are selling Motus GI stock?

MOTS stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, and Alyeska Investment Group L.P..
View insider buying and selling activity for Motus GI

How do I buy shares of Motus GI?

Shares of MOTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Motus GI's stock price today?

One share of MOTS stock can currently be purchased for approximately $1.01.

How big of a company is Motus GI?

Motus GI has a market capitalization of $29.24 million and generates $110,000.00 in revenue each year. The company earns $-23,090,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Motus GI employs 44 workers across the globe.

What is Motus GI's official website?

The official website for Motus GI is www.motusgi.com.

How can I contact Motus GI?

Motus GI's mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company can be reached via phone at 954-541-8000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.